{
  "id": "resp_08058b4f339277a000693c914f3488819096d787d42b03555d",
  "object": "response",
  "created_at": 1765577039,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_08058b4f339277a000693c914fb6e48190829a799251097b72",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08058b4f339277a000693c916385bc8190b601c3b36224591d",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12 inhibitor clinical trial triple-negative breast cancer"
      }
    },
    {
      "id": "rs_08058b4f339277a000693c916584b08190845577b17f3309fd",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08058b4f339277a000693c916ec2848190aca8b7b5950c60ff",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12 inhibitor drug development company CDK12 clinical trial"
      }
    },
    {
      "id": "rs_08058b4f339277a000693c9171096c819094a814eee5ee90b6",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_08058b4f339277a000693c9183ea9481908e664e3fe662475f",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCI triple-negative breast cancer definition"
      }
    },
    {
      "id": "rs_08058b4f339277a000693c9185a9848190ac60838bdb36a2eb",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_08058b4f339277a000693c9194ac04819082a9b66c3d409968",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": false,\n  \"assets\": [],\n  \"rejected_reason\": \"Candidate identifier \\\"triple-negative breast cancer (TNBC)\\\" is an indication/disease entity (see NCI definition: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/triple-negative-breast-cancer), not a specific drug/asset identifier; therefore required drug-asset fields (drug_name_code, sponsor, target, modality, development_stage, geography) cannot be populated.\"\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 19271,
    "input_tokens_details": {
      "cached_tokens": 4736
    },
    "output_tokens": 3981,
    "output_tokens_details": {
      "reasoning_tokens": 3871
    },
    "total_tokens": 23252
  },
  "user": null,
  "metadata": {}
}